Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us ![]()
About
PEGS Boston SummitPEGS Boston Summit
Not Confirmed
Not Confirmed
11 May-15 November, 2026
Not Confirmed
Not Confirmed
03-05 June, 2026
Peptide Therapeutics F...Peptide Therapeutics Forum 2026
Not Confirmed
Not Confirmed
04-05 June, 2026
List your booth number for exhibitions, ask us
CONTACT DETAILS




Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
PEGS Boston SummitPEGS Boston Summit
Industry Trade Show
Not Confirmed
11 May-15 November, 2026
Industry Trade Show
Not Confirmed
03-05 June, 2026
Peptide Therapeutics F...Peptide Therapeutics Forum 2026
Industry Trade Show
Not Confirmed
04-05 June, 2026
Digital content

27 May 2026
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/biolinerx-reports-first-quarter-2026-financial-results-and-provides-corporate-update-302782918.html

22 May 2026
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/biolinerx-and-hemispherian-as-highlight-new-data-on-glix1-at-the-american-society-of-clinical-oncology-asco-2026-annual-meeting-302777984.html

20 May 2026
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/biolinerx-to-report-first-quarter-2026-results-on-may-27-2026-302777565.html

19 May 2026
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/biolinerx-and-hemispherian-announce-new-glix1-data-demonstrating-potent-anti-tumor-effect-in-glioblastoma-gbm-across-multiple-in-vivo-studies-including-a-temozolomide-tmz-resistant-model-with-patient-derived-xenografts-302775997.html

28 Apr 2026
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/biolinerx-and-hemispherian-announce-first-patient-dosed-in-phase-12a-study-of-glix1-for-the-treatment-of-glioblastoma-gbm-302755515.html

26 Mar 2026
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/biolinerx-announces-initiation-of-phase-12a-study-of-glix1-for-the-treatment-of-glioblastoma-gbm-302725980.html
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE